Search Results

By Daryl E. Pritchard, PhD  / October 2026

The Molecular Watchman: Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers

Implementing a personalized medicine approach in oncology increasingly includes the use of measurable residual disease (MRD) testing to detect molecular evidence of cancer that remains after treatment, enabling more precise risk stratification, earlier intervention, and more informed treatment...